[go: up one dir, main page]

WO2009095489A3 - Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling - Google Patents

Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling Download PDF

Info

Publication number
WO2009095489A3
WO2009095489A3 PCT/EP2009/051093 EP2009051093W WO2009095489A3 WO 2009095489 A3 WO2009095489 A3 WO 2009095489A3 EP 2009051093 W EP2009051093 W EP 2009051093W WO 2009095489 A3 WO2009095489 A3 WO 2009095489A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid sequences
polypeptides
directed against
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/051093
Other languages
French (fr)
Other versions
WO2009095489A2 (en
Inventor
Els Anna Alice Beirnaert
Marc Jozef Lauwereys
Patrick Stanssens
Cedric Jozef Neotere Ververken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
Original Assignee
Ablynx NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV filed Critical Ablynx NV
Publication of WO2009095489A2 publication Critical patent/WO2009095489A2/en
Publication of WO2009095489A3 publication Critical patent/WO2009095489A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to amino acid sequences that are directed against (as defined herein) Interleukin-6 Receptor (IL-6R), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
PCT/EP2009/051093 2008-02-01 2009-01-30 Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling Ceased WO2009095489A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6320808P 2008-02-01 2008-02-01
US6317408P 2008-02-01 2008-02-01
US6335608P 2008-02-01 2008-02-01
US61/063,356 2008-02-01
US61/063,208 2008-02-01
US61/063,174 2008-02-01

Publications (2)

Publication Number Publication Date
WO2009095489A2 WO2009095489A2 (en) 2009-08-06
WO2009095489A3 true WO2009095489A3 (en) 2009-10-01

Family

ID=40635441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/051093 Ceased WO2009095489A2 (en) 2008-02-01 2009-01-30 Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling

Country Status (1)

Country Link
WO (1) WO2009095489A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2041177E (en) 2006-06-02 2012-03-05 Regeneron Pharma ANTIBODIES WITH HIGH AFFINITY FOR THE HUMAN IL-6 RECEPTOR
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
EP2417162A2 (en) 2009-04-10 2012-02-15 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
CA2758191C (en) 2009-04-10 2015-06-30 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2011032119A1 (en) 2009-09-14 2011-03-17 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
US20110195494A1 (en) 2009-10-02 2011-08-11 Boehringer Ingelheim International Gmbh Dll4-binging molecules
US20110172398A1 (en) 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
JO3417B1 (en) 2010-01-08 2019-10-20 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
AU2012311443B2 (en) 2011-09-23 2016-12-01 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
TWI589299B (en) 2011-10-11 2017-07-01 再生元醫藥公司 Composition for treating rheumatoid arthritis and method of use thereof
WO2016062766A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
PL3475699T3 (en) 2016-06-23 2022-09-26 Ablynx N.V. Improved pharmacokinetic assays for immunoglobulin single variable domains
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
KR20210122810A (en) 2019-01-31 2021-10-12 사노피 바이오테크놀로지 Anti-IL-6 receptor antibody for the treatment of juvenile idiopathic arthritis
CN114651010A (en) 2019-04-24 2022-06-21 赛诺菲生物技术公司 Diagnosis and Treatment of Rheumatoid Arthritis
EP3980459A1 (en) 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0628639B1 (en) * 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
WO2007104529A2 (en) * 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2008020079A1 (en) * 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
WO2008071685A1 (en) * 2006-12-13 2008-06-19 Ablynx N.V. Polypeptides specific for complexes involved in receptor-mediated signaling, such as the il-6/il-6 receptor complex
WO2009010539A2 (en) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) from macaca fascicularis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0628639B1 (en) * 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
WO2007104529A2 (en) * 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2008020079A1 (en) * 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
WO2008071685A1 (en) * 2006-12-13 2008-06-19 Ablynx N.V. Polypeptides specific for complexes involved in receptor-mediated signaling, such as the il-6/il-6 receptor complex
WO2009010539A2 (en) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) from macaca fascicularis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CACIA J ET AL: "Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: Identification and effect on binding affinity", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 35, no. 6, 13 February 1996 (1996-02-13), pages 1897 - 1903, XP002094430, ISSN: 0006-2960 *
CHOY E H S ET AL: "Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, vol. 46, no. 12, 1 December 2002 (2002-12-01), pages 3143 - 3150, XP002298379, ISSN: 0004-3591 *
GEIGER T ET AL: "Deamidation isomerization and racemization at asparaginyl and aspartyl residues in peptides", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 262, no. 2, 15 January 1987 (1987-01-15), pages 785 - 794, XP002966442, ISSN: 0021-9258 *
HOLLIGER PHILIPP ET AL: "ENGINEERED ANTIBODY FRAGMENTS AND THE RISE OF SINGLE DOMAINS", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 23, no. 9, 1 September 2005 (2005-09-01), pages 1126 - 1136, XP008076746, ISSN: 1087-0156 *
ITO HIROAKI ET AL: "A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.", GASTROENTEROLOGY APR 2004, vol. 126, no. 4, April 2004 (2004-04-01), pages 989 - 996 ; dis, XP002528800, ISSN: 0016-5085 *
NISHIMOTO NORIHIRO ET AL: "Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 106, no. 8, 1 October 2005 (2005-10-01), pages 2627 - 2632, XP002463362, ISSN: 0006-4971 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R

Also Published As

Publication number Publication date
WO2009095489A2 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
WO2009095489A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
TN2012000393A1 (en) Agonist dr5 binding polypeptides
EP3461844A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
PH12013502234A1 (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
WO2010142551A8 (en) Amino acid sequences directed against receptors to cytokines belonging to the il-17 family
WO2010130830A3 (en) Anti-sclerostin vhh and their use for treating bone diseases
WO2007112940A3 (en) Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
WO2011028344A3 (en) Interleukin-1 receptor antagonist compositions and methods of making and using same
MX2010005783A (en) Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same.
WO2008101985A3 (en) Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
WO2009155001A3 (en) Wnt protein signalling inhibitors
WO2008074840A3 (en) Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
GT201200189A (en) PCSK9 ANTAGONISTS
EA201290964A1 (en) Peptide Conjugates of GLP-1 Receptor Agonists and Their Use
WO2006104913A3 (en) USE OF ANTI-TNF OR ANTI-ILl RNAI TO SUPPRESS PRO- INFLAMMATORY CYTOKINE ACTIONS LOCALLY TO TREAT PAIN
WO2008157378A8 (en) Rage fusion proteins
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2008113515A3 (en) huTNFR1 SELECTIVE ANTAGONISTS
WO2009138494A3 (en) Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors
WO2008095622A3 (en) SECRETED LUCIFERASE MLuc7 AND USE THEREOF
WO2010040736A3 (en) Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
WO2009135953A3 (en) Amino acid sequences directed against integrins and uses thereof
WO2010042685A3 (en) Inhibitors of the atb(0,+) transporter and uses thereof
WO2007045019A3 (en) Polyoleosins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09706174

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09706174

Country of ref document: EP

Kind code of ref document: A2